IP Library Assignment 061402/0236
Patent Assignment
Reel/Frame 061402/0236

Release of Security Interest in Specified Patents

Recorded: 2022-09-09 Pages: 8
Assignor
THE BANK OF NEW YORK MELLON
Executed: 2017-12-19
Assignee
SPROUT PHARMACEUTICALS, INC.
4350 LASSITER AT NORTH HILLS AVE #260, RALEIGH, NORTH CAROLINA, 27609
Covered Properties (18)
New benzimidazolone derivatives having mixed serotonin and dopamine receptors affinity
Patent: 6,281,218 →
Application: 09/634,120 →
N,N'-Disubstituted Benzimidazolone Derivatives with Affinity at the Serotonin and Dopamine Receptors
Patent: 6,521,623 →
Application: 09/933,598 →
Publication: US 2003/0027823
Benzimidazolone Derivatives Displaying Affinity at the Serotonin and Dopamine Receptors
Patent: 6,586,435 →
Application: 09/933,609 →
Publication: US 2002/0103208
Stable Polymorph of Flibanserin
Patent: 7,183,410 →
Application: 10/210,474 →
Publication: US 2003/0119850
A Method of Treating Female Hypoactive Desire Disorder with Flibanserin
Patent: 7,151,103 →
Application: 10/272,603 →
Publication: US 2003/0104980
Treating Sexual Desire Disorders with Flibanserin
Patent: 8,227,471 →
Application: 11/524,268 →
Publication: US 2007/0072872
Stable Polymorph of Flibanserin
Patent: 7,420,057 →
Application: 11/546,304 →
Publication: US 2007/0032655
Use of Flibanserin in the Treatment of Obesity
Patent: 8,227,476 →
Application: 11/997,567 →
Publication: US 2008/0242678
Benzimidazolone Derivatives for the Treatment of Premenstrual and Other Female Sexual Disorders
Patent: 7,923,449 →
Application: 12/091,848 →
Publication: US 2008/0242679
Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity
Patent: 8,722,682 →
Application: 12/518,574 →
Publication: US 2011/0015207
Use of Flibanserin in the Treatment of Obesity
Patent: 8,785,458 →
Application: 13/550,062 →
Publication: US 2013/0079355
Salts
Patent: 9,546,141 →
Application: 14/484,900 →
Publication: US 2015/0126524
Treatment of Vasomotor Symptoms
Application: 14/583,275 →
Publication: US 2015/0250783
Treating Sexual Desire Disorders with Flibanserin
Patent: 9,468,639 →
Application: 14/640,055 →
Publication: US 2015/0342948
Flibanserin for the Treatment of Urinary Incontinence and Related Diseases
Patent: 9,763,936 →
Application: 14/809,862 →
Publication: US 2016/0051545
Pharmaceutical compositions containing flibanserin
Application: 14/867,779 →
Publication: US 2016/0095819
Use of Flibanserin in the Treatment of Obesity
Patent: 9,730,927 →
Application: 14/940,802 →
Publication: US 2016/0136161
Treating Sexual Desire Disorders with Flibanserin
Patent: 9,782,403 →
Application: 15/270,167 →
Publication: US 2017/0100392
Related Assignments (9)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Agreement Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →
Security Agreement May 25, 2017
From: ALDEN OPTICAL LABORATORIES, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 042584/0861 →
Security Interest Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
Security Interest Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
Corrective Assignment to Correct the Typographical Error in the Assignment Us Patent 10,098,987 Should Have Been Identified as 10,098,876 and Us Patent 8,785,485 Should Have Been Identified as 8,785,458. Which Incorrectly Identified Previously Recorded on Reel 055407 Frame 0810. Assignor(S) Hereby Confirms the Security Interest. Mar 1, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055467/0791 →
Release of Security Interest in Specified Patents Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0194 →
Release of Security Interest in Specified Patents Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061401/0684 →
Security Interest Apr 13, 2023
From: SPROUT PHARMACEUTICALS, INC.
To: HOLLAND, ANNE; MCGLOTHLIN, SANDRA
Reel/Frame 063320/0136 →
Release of Security Interest Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →